NO20032007L - Radiofarmasöytika for diagnostisering av Alzheimers sykdom - Google Patents

Radiofarmasöytika for diagnostisering av Alzheimers sykdom

Info

Publication number
NO20032007L
NO20032007L NO20032007A NO20032007A NO20032007L NO 20032007 L NO20032007 L NO 20032007L NO 20032007 A NO20032007 A NO 20032007A NO 20032007 A NO20032007 A NO 20032007A NO 20032007 L NO20032007 L NO 20032007L
Authority
NO
Norway
Prior art keywords
radiopharmaceuticals
alzheimer
diagnosis
disease
Prior art date
Application number
NO20032007A
Other languages
English (en)
Other versions
NO20032007D0 (no
Inventor
Christoph-Stephan Hilger
Bernd Johannsen
Joerg Steinbach
Peter Maeding
Meredith Halks-Miller
Richard Horuk
Harald Dinter
Raju Mohan
Joseph E Hesselgesser
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO20032007D0 publication Critical patent/NO20032007D0/no
Publication of NO20032007L publication Critical patent/NO20032007L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NO20032007A 2000-11-06 2003-05-05 Radiofarmasöytika for diagnostisering av Alzheimers sykdom NO20032007L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24629900P 2000-11-06 2000-11-06
PCT/EP2001/012607 WO2002036581A1 (en) 2000-11-06 2001-11-01 Radiopharmaceuticals for diagnosing alzheimer's disease

Publications (2)

Publication Number Publication Date
NO20032007D0 NO20032007D0 (no) 2003-05-05
NO20032007L true NO20032007L (no) 2003-07-02

Family

ID=22930075

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20032007A NO20032007L (no) 2000-11-06 2003-05-05 Radiofarmasöytika for diagnostisering av Alzheimers sykdom

Country Status (29)

Country Link
US (2) US6676926B2 (no)
EP (1) EP1332138B1 (no)
JP (1) JP4234425B2 (no)
KR (1) KR20030045167A (no)
CN (1) CN1473158A (no)
AR (1) AR035366A1 (no)
AT (1) ATE314354T1 (no)
AU (2) AU2002214034B2 (no)
BG (1) BG107762A (no)
BR (1) BR0115150A (no)
CA (1) CA2424598A1 (no)
DE (1) DE60116365T2 (no)
EA (1) EA006199B1 (no)
EE (1) EE200300216A (no)
HR (1) HRP20030459A2 (no)
HU (1) HUP0301710A3 (no)
IL (1) IL155191A0 (no)
JO (1) JO2207B1 (no)
MX (1) MXPA03003759A (no)
NO (1) NO20032007L (no)
NZ (1) NZ525303A (no)
PE (1) PE20020531A1 (no)
PL (1) PL361631A1 (no)
SK (1) SK287495B6 (no)
TW (1) TWI238820B (no)
UY (1) UY27003A1 (no)
WO (1) WO2002036581A1 (no)
YU (1) YU33203A (no)
ZA (1) ZA200304409B (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY27003A1 (es) * 2000-11-06 2002-07-31 Schering Ag Productos radiofarmacéuticos para el diagnóstico de la enfermedad de alzheimer
OA12670A (en) 2001-10-22 2006-06-20 Pfizer Prod Inc Piperazine derivatives with ccr1 receptor antagonist activity.
JP5082033B2 (ja) 2001-12-21 2012-11-28 エグゼリクシス パテント カンパニー エルエルシー Ｌｘｒのモジュレーター
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
JP2006525279A (ja) * 2003-05-07 2006-11-09 シエーリング アクチエンゲゼルシャフト 求核性フッ素化装置及び方法
US9017724B2 (en) 2004-02-24 2015-04-28 The General Hospital Corporation Catalytic radiofluorination
AU2005216949B2 (en) * 2004-02-24 2011-09-22 The General Hospital Corporation Catalytic radiofluorination
US8257680B1 (en) 2004-02-24 2012-09-04 The General Hospital Corporation Catalytic radiofluorination
GB0409236D0 (en) * 2004-04-26 2004-05-26 Novartis Ag Organic compounds
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
KR100778888B1 (ko) * 2005-11-29 2007-11-28 재단법인서울대학교산학협력재단 베타아밀로이드 펩타이드 플라크의 영상화를 위한벤질리덴아닐린 계열의 유도체 및 그의 방사성 동위원소표지화합물
CA2663121C (en) 2006-09-08 2016-01-19 Rhode Island Hospital Treatment, prevention, and reversal of alcohol-induced brain disease
EP2061484B1 (en) 2006-09-08 2012-11-07 Rhode Island Hospital Treatment, prevention, and reversal of alcohol-induced liver disease
CN101563305A (zh) * 2006-12-21 2009-10-21 哈默史密斯网上成像有限公司 放射性标记方法
GB0625523D0 (en) 2006-12-21 2007-01-31 Ge Healthcare Ltd In vivo imaging agents
CA2703563A1 (en) * 2007-10-31 2009-05-07 Alseres Pharmaceuticals, Inc. Methods for diagnosing and monitoring treatment of lewy body dementia by assessing dopamine transporter level
JP5501339B2 (ja) 2008-03-21 2014-05-21 ザ ジェネラル ホスピタル コーポレイション アルツハイマー病及び関連疾患の検出及び治療のための化合物及び組成物
EP2161256A1 (en) * 2008-09-08 2010-03-10 Atomic Energy Council - Institute of Nuclear Energy Research Compound containing carboxylate ester and N2S2 ligand bi-functional groups and manufacturing method thereof
EP2163541A1 (en) * 2008-09-12 2010-03-17 Bayer Schering Pharma Aktiengesellschaft Piperazine derivatives for binding and imaging amyloid plaques and their use
WO2011041470A2 (en) * 2009-09-30 2011-04-07 Mallinckrodt Inc. Sustained-release opiate and opiate derivative compositions
TW201201846A (en) * 2010-02-08 2012-01-16 Bayer Schering Pharma Ag Iodo precursor for a PET imaging agent of amyloid plaques
WO2011110511A1 (en) * 2010-03-11 2011-09-15 Bayer Pharma Aktiengesellschaft Spect imaging agents of amyloid plaques
WO2012159107A1 (en) 2011-05-19 2012-11-22 Rhode Island Hospital Inhibition of renal fibrosis
US11623946B2 (en) 2013-12-27 2023-04-11 National University Corporation Tokyo Medical And Dental University Diagnosis methods, diagnostic agents, and therapeutic agents against alzheimer's disease and frontotemporal lobar degeneration, and screening methods for these agents
HRP20211156T1 (hr) * 2015-08-28 2021-12-24 Chdi Foundation, Inc. Kontrastna sredstva za slikovnu dijagnostiku huntingtin proteina

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06510021A (ja) 1991-03-13 1994-11-10 ザ リージェンツ オブ ザ ユニバーシティ オブ ミネソタ アルツハイマー病検出用の放射性薬剤
EP0524146A1 (de) 1991-07-19 1993-01-20 Ciba-Geigy Ag Aminosubstituierte Piperazinderivate
GB9413772D0 (en) 1994-07-08 1994-08-24 Wyeth John & Brother Ltd 5-HT1A ligands
US5919797A (en) * 1996-04-24 1999-07-06 Emory University Halogenated naphthyl methoxy piperidines for mapping serotonin transporter sites
JP2000516210A (ja) 1996-07-12 2000-12-05 ロイコサイト，インコーポレーテッド ケモカインレセプターアンタゴニストとその使用方法
FR2758328B1 (fr) 1997-01-15 1999-04-02 Pf Medicament Nouvelles amines aromatiques derivees d'amines cycliques utiles comme medicaments
US6207665B1 (en) * 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents
AUPP278498A0 (en) * 1998-04-03 1998-04-30 Australian Nuclear Science & Technology Organisation Peripheral benzodiazepine receptor binding agents
US6288083B1 (en) 1998-09-04 2001-09-11 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
AUPP818099A0 (en) 1999-01-14 1999-02-11 Fujisawa Pharmaceutical Co., Ltd. New n-containing heterocyclic compounds
SK11822001A3 (sk) 1999-03-26 2002-09-10 Astrazeneca Ab Modulátory chemokínovej aktivity, spôsoby ich prípravy, farmaceutické kompozície s ich obsahom a ich použitie v terapii
UY27003A1 (es) * 2000-11-06 2002-07-31 Schering Ag Productos radiofarmacéuticos para el diagnóstico de la enfermedad de alzheimer

Also Published As

Publication number Publication date
AR035366A1 (es) 2004-05-12
US20020131932A1 (en) 2002-09-19
KR20030045167A (ko) 2003-06-09
PL361631A1 (en) 2004-10-04
TWI238820B (en) 2005-09-01
ATE314354T1 (de) 2006-01-15
EP1332138B1 (en) 2005-12-28
BG107762A (en) 2004-03-31
EP1332138A1 (en) 2003-08-06
JP2004513123A (ja) 2004-04-30
NO20032007D0 (no) 2003-05-05
DE60116365T2 (de) 2006-08-24
EE200300216A (et) 2003-08-15
SK5472003A3 (en) 2003-10-07
JP4234425B2 (ja) 2009-03-04
DE60116365D1 (de) 2006-02-02
ZA200304409B (en) 2004-09-06
HUP0301710A3 (en) 2007-03-28
CA2424598A1 (en) 2002-05-10
HRP20030459A2 (en) 2005-04-30
NZ525303A (en) 2004-10-29
AU2002214034B2 (en) 2006-01-05
HUP0301710A2 (hu) 2003-11-28
YU33203A (sh) 2006-05-25
IL155191A0 (en) 2003-11-23
EA006199B1 (ru) 2005-10-27
WO2002036581A1 (en) 2002-05-10
AU1403402A (en) 2002-05-15
CN1473158A (zh) 2004-02-04
US6872381B1 (en) 2005-03-29
UY27003A1 (es) 2002-07-31
JO2207B1 (en) 2004-10-07
PE20020531A1 (es) 2002-06-15
MXPA03003759A (es) 2003-07-28
BR0115150A (pt) 2003-12-30
SK287495B6 (sk) 2010-12-07
US6676926B2 (en) 2004-01-13
EA200300507A1 (ru) 2003-12-25

Similar Documents

Publication Publication Date Title
NO20032007L (no) Radiofarmasöytika for diagnostisering av Alzheimers sykdom
NO20026199D0 (no) Forbindelser for behandling av Alzheimers sykdom
PT2264018E (pt) Derivados de tioflavina para uso no diagnóstico da doença de alzheimer
DK1944040T3 (da) Analysefremgangsmåde for Alzheimers sygdom
NO20002380D0 (no) Forbindelser for før-døden diagnose av Alzheimers sykdom og in vivo billeddannelse, samt forhindring av amyloid deponering
DK1392287T3 (da) Anvendelse af substituerede azetidinonderivater i behandlingen af Alzheimers sygdom
NO20054640D0 (no) Fremgangsmater for behandling av Parkinsons sykdom
NO944928D0 (no) Fremgangsmåter for inhibering av Alzheimers sykdom
DK1303272T3 (da) Benzothiazolderivater til behandling af Alzheimers sygdom og Parkinsons sygdom
AU2610901A (en) Predictive diagnostic for alzheimer's disease
NO20001869L (no) FremgangsmÕte for behandling av Alzheimers sykdom
ITMI20010985A0 (it) Farmaci per il morbo di alzheimer
AU2002315131A1 (en) Aminediols as agents for the treatment of alzheimer's disease
AU2001236592A1 (en) Methods for diagnosis of alzheimer's disease
NO20010953D0 (no) En fremgangsmÕte for behandling av stafylokokkal sykdom
IL175004A0 (en) Quick test for the diagnosis of alzheimer's disease
EP1181550A4 (en) METHODS OF IDENTIFYING COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
NO20024746D0 (no) Anvendelse av galantamin ved behandling av nevropsykiatrisk oppförsel assosiert med Alzheimers sykdom
NO20025790L (no) Syntesefremgangsmåte for fluormetyleringen av alkoholer
AU2003236714A8 (en) Diagnosis of alzheimer's disease based on the habeta42:habeta40 ratio
NO20012612D0 (no) Isonipecotamider for behandling av integren-formidlede lidelser
IL172690A0 (en) Methods for the diagnosis and prognosis of alzheimer's disease
AU2003299101A1 (en) Compounds for the treatment of alzheimer's disease
EP1693671A4 (en) METHOD FOR DIAGNOSING ALZHEIMER'S DISEASE
GB0012123D0 (en) Alzheimer's disease assay